Medicus Pharma Ltd. MDCX
1.83 USD -0.05 (-2.92%)
At closeNov 11, 2026, 7:00 AM EST
1.89 +0.06 +3.05%
Pre-market · Nov 11, 7:00 AM ET
1.72 Day range 2.10
1.70 52-week range 127.50
- YTD
- -97.61%
- 1 year
- -98.45%
News
seekingalpha.com Medicus Pharma Ltd. (MDCX) Q3 2026 Earnings Call Transcript Medicus Pharma Ltd. ( MDCX ) Q3 2026 Earnings Call November 9, 2026 11:30 AM EST Company Participants Anna Baran-Djokovic - Senior Vice President of Investor Relations Raza Bokhari - CEO & Executive…
benzinga.com Medicus Pharma Q3 2026 Earnings Call Transcript Medicus Pharma (NASDAQ:MDCX) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline Medicus Pharma advances its Pfizer-partnered cancer asset and plans a $135 million SkinJect SPAC deal while reducing quarterly operating expenses.
benzinga.com Medicus Pharma Q3 EPS $(11.64) Misses $(6.63) Estimate Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(11.64) per share which missed the analyst consensus estimate of $(6.63) by 75.83 percent. This is a 79.21 percent increase over losses of…
globenewswire.com Medicus Pharma to Present at BIO-Europe 2026 Medicus Chief Medical Officer will Highlight Company's Focus on Precision Oncology, Anchored by CD228V targeted ADC and Partner Ready Therapeutic Programs Medicus Chief Medical Officer will Highlight…
globenewswire.com Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing the clinical…
globenewswire.com Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent Financing PHILADELPHIA, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and…
benzinga.com Dow Falls Over 100 Points; US Initial Jobless Claims Decline U.S. stocks fell Thursday, led by tech, while energy rose and oil jumped 4.8%. Jobless claims eased to 197,000; small caps posted sharp swings.
benzinga.com Why Applied Digital Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket Applied Digital shares rise after Q1 revenue and loss beat estimates; Xiao-I and iPower lead gainers, while China SXT and Medicus Pharma fall.
benzinga.com Medicus Pharma (MDCX) Shares Fall 24% After Hours: Here's Why Medicus Pharma shares fall 24% after hours as the company announces a 50-to-1 share consolidation.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Valneva (NASDAQ:VALN) shares rose 20.6% to $7.09 during Wednesday's after-market session. The company's market cap stands at $555.6 million. Profound Medical (NASDAQ:PROF) stock rose 16.98%…
benzinga.com Medicus Pharma Files Optimized Seamless Phase 2b/3 Registration-Intent Protocol To FDA For Teverelix To Treat Advanced Prostate Cancer Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today…
benzinga.com Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus Medicus Pharma narrows SkinJect development to Gorlin syndrome, targeting a $1.1 billion market and seeking key FDA orphan designations.
benzinga.com Medicus Pharma And Yorkville Mutually Agree To Terminate Standby Equity Purchase Agreement For Up To $15M Of Stock On September 11, 2026, Medicus Pharma Ltd. (the "Company") and YA II PN, LTD. ("Yorkville") mutually agreed to terminate the Standby Equity Purchase Agreement, dated as of February 10, 2025, between…
benzinga.com Medicus Pharma Posts Phase 2 Clinical Study Report For SKNJCT‑003 On ClinicalTrials.gov, Offering Public Access To Efficacy, Safety, And Drug‑Delivery Findings Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today…
benzinga.com Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion Medicus Pharma partners with Pfizer to commercialize CD228V in a licensing deal worth over $1 billion plus royalties.
benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers Cypherpunk Technologies (NASDAQ:CYPH) shares rose 30.4% to $2.19 during Thursday's regular session. The market value of their outstanding shares is at $181.0 million. bioAffinity Technologies…
benzinga.com Nasdaq Gains Over 200 Points; US Weekly Jobless Claims Edge Higher U.S. stocks climbed, led by Nasdaq; communications shares rose, energy fell, while MIMI surged and RARE plunged after trial failures.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Gelteq (NASDAQ:GELS) shares increased by 38.6% to $0.97 during Thursday's pre-market session. The company's market cap stands at $7.4 million. bioAffinity Technologies (NASDAQ:BIAF) shares…- benzinga.com Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.13) by 61.54 percent. This is a 51.16 percent increase over losses of…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Universe Pharmaceuticals (NASDAQ:UPC) stock increased by 91.1% to $6.04 during Friday's after-market session. The company's market cap stands at $2.2 million. BGM Group (NASDAQ:BGM) stock…
benzinga.com EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi Medicus Pharma obtained UAE approval for its PRECISION-E2 Phase 2a clinical trial testing Teverelix in endometriosis patients.
benzinga.com Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) shares moved upwards by 41.1% to $0.09 during Friday's after-market session. The market value of their outstanding shares is at $12.7 million. iTonic…- benzinga.com Medicus Pharma Announces Positive FDA Feedback For Its Optimized Phase 2 Clinical Trial Of Teverelix In Men Following A First Episode Of Acute Urinary Retention Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-market session. The company's market cap stands at $1.7 million. Medicus Pharma (NASDAQ:MDCX) stock rose…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Curis (NASDAQ:CRIS) stock rose 9.0% to $0.46 during Wednesday's after-market session. The company's market cap stands at $20.3 million. Humacyte (NASDAQ:HUMA) shares moved upwards by 5.45% to…
- benzinga.com Medicus Pharma To Highlight SkinJect Phase 2 Data And Teverelix Clinical Advances At BIO 2026 Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
benzinga.com Medicus Pharma Files Rare Pediatric Disease Designation Request To FDA For SkinJect Microneedle Array Patch To Treat Basal Cell Carcinoma In Participants With Gorlin Syndrome Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic…
benzinga.com Medicus Pharma Submits IND Application To DOH For PRECISION-E2, Phase 2a Genomics-Enabled Clinical Trial Evaluating Teverelix In Women With Symptomatic Endometriosis In UAE Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutic…- benzinga.com Medicus Pharma Submits Modification Application Through European Union Clinical Trials Information System For Its Phase 2b Trial Of Teverelix In Advanced Prostate Cancer Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive…
benzinga.com Medicus Pharma Submits Protocol SKNJCT-005 To FDA Under Existing IND Application, For SkinJect Into Registrational Development For Patients With Gorlin Syndrome Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
benzinga.com Medicus Pharma Receives $22M In Non-Dilutive Financing Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
benzinga.com Medicus Pharma Q1 EPS $(0.31) Misses $(0.19) Estimate Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.19) by 63.16 percent. This is a 26.19 percent increase over losses of…
benzinga.com EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study Medicus Pharma reports dose-response in Phase 2 BCC study, with 200µg cohort showing the strongest efficacy and safety profile at Day 57.- benzinga.com Medicus Pharma Highlights Results From Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis; Says Data Reveal 'a clear and consistent dose-response relationship across endpoints' 200μg Cohort Achieves 55% Complete Response at Day 57 Emerging asRegistrational Grade Lead RegimenThe pre-specified expanded dataset analysis builds on this foundation by: Revealing a clear and…
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga.com Why Organon Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket Organon & Co (OGN) jumped 14.8% in pre-market trading as Sun Pharma agreed to acquire the company for $11.75 billion, $2 higher than current price.- benzinga.com Medicus Pharma Files Orphan Drug Designation To FDA For SkinJect To Treat Basal Cell Carcinoma In Participants With Gorlin Syndrome Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
benzinga.com Why J B Hunt Transport Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket J B Hunt Transport Services Inc (JBHT) stock rose in pre-market trading after beating earnings estimates. Gainers include CTNT, MYSE, WNW, MDCX, WSHP, MAMO, ALIT, HQ, and SLDP while XHG and BIRD were…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com EXCLUSIVE: Penny Stock Medicus Pharma Findings Support Potential In Women's Health Pipeline Medicus Pharma to present Phase 1 Teverelix data showing dose-dependent estradiol suppression and long-acting profile at AACE 2026.
benzinga.com EXCLUSIVE: Medicus Pharma Refines Trial Design To Cut Costs, Accelerate Development For Enlarged Prostate Patients Medicus Pharma submits Phase 2 design for Teverelix, targeting faster data readouts and lower costs in benign prostatic hyperplasia- benzinga.com Medicus Pharma Issues Clarification Regarding Previously Reported Topline Results From Phase 2 Clinical Study Of SKNJCT-003 In Nodular Basal Cell Carcinoma Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
- benzinga.com Medicus Pharma Reports ~80% Overall Response Rate, 73% Clinical Clearance From Clinical Validation Of Phase 2 SkinJect Dataset Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
- benzinga.com Medicus Pharma To Present New Analysis From Its Phase 2 SkinJect Trial Medicus Pharma Ltd. (NASDAQ:MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development programs of novel and potentially disruptive therapeutics…
- benzinga.com Medicus Pharma Q4 EPS $(0.83) Misses $(0.15) Estimate Medicus Pharma (NASDAQ:MDCX) reported quarterly losses of $(0.83) per share which missed the analyst consensus estimate of $(0.15) by 442.48 percent.
- benzinga.com Medicus Pharma To Update Review Of SkinJect SKNJCT-003 Phase 2 Clinical Trial Topline Results In Fireside Chat Hosted By Brookline Capital Markets Biotechnology Equity Research Analyst Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.PHILADELPHIA, PA / ACCESS…
- benzinga.com Medicus Pharma Says SkinJect Phase 2 Principal Investigator And KOL, Babar Rao To Provide Clinical Interpretation Of Data During Business Update Webcast On March 26 Phase 2 Study Demonstrated 73% clinical Clearance in the 200-µg Arm suggests that ~3 out of 4 treated lesions may allow patients to avoid immediate surgical intervention.PHILADELPHIA, March 16, 2026…